AstraZeneca is weighing a roughly $10 billion acquisition of Rhythm Pharmaceuticals, according to a report in The Wall Street Journal, a move that would deepen the British drugmaker's push into obesity treatments. The news sent Rhythm's shares up 28%, a sign investors see the approach as credible rather than idle speculation.
The Journal reported that AstraZeneca floated an offer of about $124 a share last month and has since renewed its interest. AstraZeneca declined to comment on the report, and Rhythm did not respond to requests for comment. Rhythm closed at $110.68, giving it a market value of around $7.6 billion, according to LSEG data — meaning the reported offer represents a premium to where the stock was already trading.
Why Rhythm is a target
Rhythm is a small but established player in obesity treatments, focused on rare genetic and metabolic disorders rather than the mass-market weight-loss drugs that have dominated headlines. Its drug Imcivree already has US approval and targets genetic forms of obesity — a narrow but clinically important niche where patients have few alternatives.
That focus makes Rhythm a different kind of asset from the blockbuster GLP-1 drugs sold by Novo Nordisk and Eli Lilly, which are designed for broad populations and have become some of the best-selling medicines in the world. Rare-disease treatments typically command high prices per patient and face less direct competition, but they also serve far smaller markets. For a large pharmaceutical company, buying an approved rare-obesity drug can be a way to add a specialised, defensible product without competing head-on in the crowded mass-market obesity space.
Large drugmakers have been active acquirers of late-stage and approved assets as they look to replenish pipelines ahead of patent expirations on older medicines. Deals in the $10 billion range are meaningful but not transformational for a company of AstraZeneca's size, which makes this the kind of bolt-on acquisition that can be absorbed without straining the balance sheet.
What it means for investors
For everyday investors, the most immediate takeaway is the size of the jump in Rhythm's share price. A 28% move in a single session reflects the market rapidly repricing the odds of a deal. When a stock trades below a reported offer price — as Rhythm does at $110.68 versus the roughly $124 a share mentioned by the Journal — it usually signals that investors are not fully convinced a deal will happen, or that they expect a different final price.
That gap is worth understanding. In merger situations, the spread between the market price and the reported offer reflects uncertainty: the deal could fall apart, a rival bidder could emerge, or the talks could drag on. It also reflects timing — money received later is worth less today. Investors who buy into a takeover target are effectively betting on the deal closing, and they take on the risk that it does not.
For AstraZeneca shareholders, the calculus is different. A $10 billion purchase would be a modest outlay relative to the company's overall value, so the deal is unlikely to move the stock dramatically on its own. What matters more is whether the acquisition adds a durable growth driver. Companies in this position often face questions about how a new asset fits with existing research and commercial teams, and whether the price paid will generate a return.
It is also worth noting that reports of this kind are not guarantees. Talks can end without a deal, and neither company has confirmed the discussions. AstraZeneca's refusal to comment and Rhythm's silence leave the situation officially unconfirmed, so investors should treat the report as a signal rather than a certainty.
What to watch next
The obvious next step is whether either company confirms the talks or announces a formal agreement. A confirmed deal would typically come with a specific price and terms, and the market would then focus on regulatory approval and any competing offers. If no deal materialises, Rhythm's shares could give back much of their gain, since the stock's rise is tied to the takeover speculation.
Investors will also watch the broader obesity-drug landscape. Interest in weight-loss treatments remains intense, and any move by a major drugmaker into the space — even a niche corner of it — can shift how the market values other companies with obesity assets. For now, the story is a reminder that in biotech, a single report about a potential buyer can move a stock sharply, and that the gap between rumour and a signed deal is where much of the risk lives.
